Ft. Lauderdale, Dec. 20, 2016 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"), an innovative biotech company focused on Cannabis (industrial hemp) Cannabinoid Research and Development, Nutraceuticals, Pharmaceuticals, and Medical Devices; announces the R&D of three new advanced CBD nutraceutical products and two CBD-based pharmaceutical drugs using the Company’s Cannabis CBD Patent, IP, Invention, Technology and future Technology. ETST’s International Application (PCT) for its Provisional Patent named “Cannabidiol Compositions Including Mixtures and Uses Thereof” was filed on October 8th, 2015 in regards to its Cannabis Hemp CBD (Cannabidiol) Oil. This application claims the benefit of ETST U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST U.S. Provisional Application No. 62/102,538, filed January 12, 2015.
ETST and its CEO, Dr. Michel Aube, is in discussions and working on a joint venture in Canada that will give the Company access to state of the art laboratory facilities to develop these ETST World Class Cannabis health and wellness Nutraceuticals products and Cannabis CBD-Based Pharmaceutical Drugs to help alleviate certain conditions and disorders.
ETST has chosen to target diseases for which, the benefits of CBD have already been demonstrated by different groups of researchers around the world. However, it is through ETST’s first in vitro study that results confirm the effectiveness of CBD on breast cancer, immune cell function, and human brain cells by acting as a neuroprotectant in its International (application (PCT) and provisional patent. Thus, as a result by mixing natural molecules and generic pharmaceutical drugs with CBD we intend to increase the effectiveness of CBD and improve the treatment of different diseases.
ETST’s CBD-Nutraceutical (functional food) products are designed to alleviate common symptoms and prevent illnesses. The products can improve the overall wellbeing of an individual such as; brain function, diabetes, inflammation, and immune cell functions.
ETST is targeting the above mentioned conditions as CBD continuously proves to work against each of them at cellular level. Starting with our recent research in deciphering the molecular action of CBD, ETST has been carefully choosing natural molecules that compliment or support CBD as well as developing formulations that blend CBD with whole plant extracts and pure natural molecules that are natural antioxidants and/or flavonoids. Together these ingredients work synergistically with CBD to improve detoxification of the brain and the liver, while improving immune function and diabetes. ETST’s advanced products will deliver the CBD molecule at maximum efficiency and will be available to everyone to continue improving lives worldwide.
Dr. Michel Aubé, ETST’s CEO & CSO states, “ETST CBD-Pharmaceutical Drugs will be designed to treat a variety of things including, but not limited to anxiety, depression, triple negative breast cancer, and fatty liver disease. Together, these diseases and disorders represent a massive market. Mental disorders are increasing worldwide. I look forward into soon discussing further details in regards to the R&D of our Cannabis CBD-Pharmaceutical Drug Pipeline. According to the World Health Organization, between 1990 and 2013 the number of people suffering from depression and/or anxiety increased by nearly 50%. Depression and anxiety disorders cost the global economy US$1 trillion each year. The substantial burden of anxiety-related disorders and the limitations of existing treatments give urgency to developing novel pharmaceutical treatments.”
Dr. Michel Aubé, ETST’s CEO & CSO continuos , “With my team of scientific researchers and laboratory resources in Canada, ETST now has the scientific expertise and the clinical support needed to develop these Cannabis CBD based products for the health benefit of people worldwide. Having several additional unique, advanced CBD nutraceutical products on the market will grant ETST a competitive advantage, thus consequently solidifying its leadership position in that market. Our two planned CBD-Based Pharmaceutical drugs will allow us to enter a new industry, making us one of the very few companies in this arena.
It has been shown both in vitro and in vivo that CBD can improve the efficiency of existing breast cancer chemotherapy either in an additive or synergetic manner. We already know that CBD modulates Id-1 gene expression, which is a partial explanation of the mechanism by which CBD acts on breast cancer. We will take advantage of this interaction between CBD and Id-1 expression to develop a drug against triple negative breast cancer (TNBC). There is currently no appropriate treatment for this disease. Many clinical trials with TNBC patients are comparing the effectiveness of various older and newer chemotherapy medications, used in different combinations. It will be very interesting to test the potential of CBD to improve old medicines.”
Hepatic (liver) endocannabinoid levels are similar to those in the brain and they are important in the regulation of hepatic hemodynamics, fibrogenesis, as well as lipid metabolism, and in the dysregulation of these functions in liver pathological states. CBD has been shown in vivo to be efficient in treating non-alcoholic fatty liver disease (NAFLD). NAFLD is the most common liver disease throughout the world. Several studies have demonstrated that oxidative stress is a major trigger of the progression of NAFLD to steato-hepatitis (non-alcoholic steato-hepatitis: NASH). NASH leads to exacerbation of inflammatory response and to liver cell dysfunction. A report, published by Allied Market Research, forecasts that the non-alcoholic steato-hepatitis market is expected to garner $1.6 billion by 2020 in North America alone. The high prevalence of Type II diabetes and obesity, which lead to NASH and NAFLD, will sustain that market’s growth. Type II diabetes shares many aspects of NAFLD, and other inflammatory processes in the adipose tissue and liver. Most non-alcoholic fatty liver disease patients are obese and at high risk of developing Type II diabetes. The number of patients living with diabetes worldwide is nearly 400 million and is expected to be more than 500 million by 2030.
Below Earth Science Tech has listed the FIELD OF THE INVENTION, BRIEF SUMMARY OF THE INVENTION and the BACKGROUND OF THE INVENTION for Earth Science Tech’s International Application (PCT) for its Provisional Patent named “Cannabidiol Compositions Including Mixtures and Uses Thereof” filed on October 8th, 2015 in regards to its Cannabis Hemp CBD (Cannabidiol) Oil.
Earth Science Tech International Application (PCT) on its Cannabis Hemp CBD (Cannabidiol) Invention and Provisional Patent “Cannabidiol Compositions Including Mixtures and Uses Thereof” Related to Treating Cancer, Modulation of the Immune System and Neuroprotectant.
FIELD OF THE INVENTION: The present invention relates to compositions for treating cancer, modulating the immune system, and providing neuroprotection against reactive oxygen species and lipid peroxidation using naturally occurring compounds. More particularly, the invention relates to the use of compositions containing compounds from hemp oil in the treatment of cancer, the modulation of the immune system, and the neuroprotection against reactive oxygen species and lipid peroxidation…. [Quote from the PCT Application]
BRIEF SUMMARY OF THE INVENTION: One object of the present invention is to provide a pharmaceutical composition for use in the treatment of cancer that includes Cannabidiol (CBD) and one or more of the following compounds.... Another object of the present invention is to provide a pharmaceutical composition for use in the treatment of cancer that includes hemp oil. The hemp oil is enriched with one or more of the following compounds…. Another object of the present invention is to provide a method of treating cancer (e.g., breast cancer). The method includes administering to a subject in need thereof an effective amount of a pharmaceutical composition that includes Cannabidiol (CBD) and one or more of the following compounds…. Another object of the present invention is to provide a method of treating cancer (e.g., breast cancer). The method includes administering to a subject in need thereof an effective amount of a pharmaceutical composition that includes hemp oil. The hemp oil is enriched with one or more of the following compounds…. [Quote from the PCT Application]
Another object of the present invention is to provide a method for activating the immune system. The method includes the stimulation of macrophages and the administration of the pharmaceutical compositions. Another object of the present invention is to provide a method of modulating the immune system. The method includes the administration of the pharmaceutical compositions. Another object of the present invention is to provide a method for protecting human brain cells from reactive oxygen species and/or lipid peroxidation. The method includes the administration of the pharmaceutical compositions. Another object of the present invention is to provide a method that prevents the death of human brain cells. The method includes the administration of the pharmaceutical compositions. Another object of the present invention is to provide a method that provides neuroprotection against reactive oxygen species and lipid peroxidation. The present invention utilizes hemp oil as a source of CBD and other components as a composition useful in treating or preventing cancer…. [Quote from the PCT Application]
The pharmaceutical compositions may be used either alone or in combination with other treatments of cancer. These other treatments will depend on the type of cancer and can include but are not limited to surgery, chemotherapy, radiation therapy, immune therapy and laser photothermal therapy. These other treatments can be before, after or concurrent with the use of the pharmaceutical compositions of the present invention. Pharmaceutical compositions may take the form of any acceptable pharmaceutical formulation. Pharmaceutical compositions can be formulated in a variety of different forms, such as liquid, semi-solid and solid dosage forms, such as liquid solutions (e.g., injectable and infusible solutions), dispersions or suspensions, tablets, pills, powders, liposomes and suppositories. The preferred form can depend on the intended mode of administration and therapeutic application. The pharmaceutical compositions include those suitable for parenteral (including intravenous, subcutaneous, intradermal, intramuscular, and intraarticular), topical (including dermal, transdermal, transmucosal, buccal, sublingual, and intraocular), and rectal administration, although the most suitable route may depend upon, for example, the condition and disorder of the recipient. Compositions for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the composition isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents…. [Quote from the PCT Application]
The pharmaceutical compositions and methods of the present invention may be administered concurrently or sequentially with one or more other treatment methods. These methods include but are not limited to chemotherapy, radiation therapy, immune therapy, laser photothermal therapy and surgery…. [Quote from the PCT Application]
As used herein, the phrases "treating cancer" and "treatment of cancer" mean to inhibit the replication of cancer cells, inhibit the spread of cancer, decrease tumor size, lessen or reduce the number of cancerous cells in the body, or ameliorate or alleviate the symptoms of the disease caused by the cancer. The treatment is considered therapeutic if there is a decrease in mortality and/or morbidity, or a decrease in disease burden manifest by reduced numbers of malignant cells in the body…. [Quote from the PCT Application]
A “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result. A therapeutically effective amount of the composition may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the protein to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of the composition are outweighed by the therapeutically beneficial effects…. [Quote from the PCT Application]
BACKGROUND OF THE INVENTION: Cannabidiol (“CBD”) is one of at least 85 active cannabinoids identified in hemp. It is a major phytocannabinoid, accounting for up to 40% of the plant's extract. CBD is considered to have a wider scope of therapeutic applications than tetrahydrocannabinol (“THC”). An orally-administered liquid containing CBD has recently been used to treat dravet syndrome, a rare type of epilepsy. CBD's strong anti-oxidant properties are believed to have neuroprotective and anti-ischemic effects. CBD is also believed to minimize or counteract some of the pyschotomimetic effects of THC. Due to the natural source of CBD, study of it has been limited until relatively recently and its medical benefits and effects have not been adequately studied.
U.S. Patent No. 6,630,507 titled "Cannabinoids as Antioxidants and Neuroprotectants," owned by the U.S. Department Of Health And Human Services, postulates that CBD may be an effective antiepileptic, may lower intraocular pressure in the treatment of glaucoma, demonstrates neuro-protective properties, attenuates glutamate toxicity, protects against cellular damage, protects the brain from ischemic damage, and exhibits superior antioxidant activity which can be used in the prophylaxis and treatment of oxidation associated diseases. The patent states “Oxidative associated diseases include, without limitation, free radical associated diseases, such as ischemia, ischemic reperfusion injury, inflammatory diseases, systemic lupus erythematosus, myocardial ischemia or infarction, cerebrovascular accidents (such as a thromboembolic or hemorrhagic stroke) that can lead to ischemia or an infarct in the brain, operative ischemia, traumatic hemorrhage (for example a hypovolemic stroke that can lead to CNS hypoxia or anoxia), spinal cord trauma, Down's syndrome, Crohn's disease, autoimmune diseases (e.g., rheumatoid arthritis or diabetes), cataract formation, uveitis, emphysema, gastric ulcers, oxygen toxicity, neoplasia, undesired cellular apoptosis, radiation sickness, and others. The embodiments described in U.S. Patent No. 6,630,507 are believed to be particularly beneficial in the treatment of oxidative associated diseases of the CNS, because of the ability of the cannabinoids to cross the blood brain barrier and exert their antioxidant effects in the brain. In particular embodiments of U.S. Patent No. 6,630,507, the pharmaceutical composition of the present invention is used for preventing, arresting, or treating neurological damage in Parkinson's disease, Alzheimer's disease and HIV dementia; autoimmune neurodegeneration of the type that can occur in encephalitis, and hypoxic or anoxic neuronal damage that can result from apnea, respiratory arrest or cardiac arrest, and anoxia caused by drowning, brain surgery or trauma (such as concussion or spinal cord shock)…. [Quote from the PCT Application]
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.
About Earth Science Tech, Inc. (ETST): Earth Science Tech (www.earthsciencetech.com) is a publicly traded (ETST) unique Science based Biotechnology company focused on cutting edge Nutraceuticals, Bioceuticals, Phytoceuticals and Cosmeceuticals for the Health, Wellness and Alternative Medicine Markets to help improve the quality of life for Consumers Worldwide. ETST is also dedicated to providing Natural Alternatives to prescription medications through the use of its cutting edge Nutritional and Dietary Supplements. This may include products such as its High-Grade Hemp CBD (Cannabidiol) Oil, Vitamins, Minerals, Herbs, Botanicals, Personal Care Products, Homeopathies, Functional Foods and other products. These products may be in various formulations and delivery systems including (but not limited to) capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders, and whole herbs. ETST is focused on researching and developing innovative Hemp extracts and to make them accessible Worldwide. ETST plans to be the premier supplier of the highest quality and purity of High Grade Hemp CBD (Cannabidiol) Oil. ETST's primary goal is to advance different High Quality Hemp extracts with a broad profile of Cannabinoids and additional natural molecules found in Industrial Hemp and to identify their distinct properties. The company is dedicated in offering its consumers the finest and purest quality All Natural-Organic Hemp CBD Oil while never compromising on quality. ETST High Grade Hemp CBD (Cannabidiol) Oil is classified as "food based" and therefore perfectly permissible in all 50 states and more than 40 countries. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD possesses no psychoactive qualities and presents a continuing stream of overwhelming evidence of significant Wellness benefits. With no psychoactive ingredient, Hemp CBD Oil is a ready-for-market Hemp-based Nutraceutical. The United States Food and Drug Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be "food based" and therefore saleable. These new non-psychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach. CBD (cannabidiol), a naturally occurring constituent of the Industrial Hemp plant, promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 "Cannabinoids as antioxidants and neuroprotectants." ETST does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. ETST does sell and distribute cannabis industrial hemp based products.
About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry.
FORWARD LOOKING DISCLAIMER: This release contains forward-looking statements that involve risks and uncertainties. Readers are referred to the Securities and Exchange Commission filings filed by the Company on EDGAR at http://www.sec.gov/edgar.shtml, specifically the most recent reports which identify important risk facts that could cause actual results to differ from those contained in the forward-looking statements. The Company undertakes no obligation to review or confirm analysts' expectations or estimates or to publicly release any revisions to any forward-looking statements. The information contained in this press release should not be construed as any indication of the Company's future stock price, its revenues or results of operations.
Earth Science Tech, Inc. (ETST)